Immunome, Inc.
IMNM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.15 | 1.21 | 0.05 | -0.03 |
| FCF Yield | -4.04% | -6.22% | -10.61% | -6.52% |
| EV / EBITDA | -13.39 | -14.63 | -6.41 | -9.59 |
| Quality | ||||
| ROIC | -22.45% | -17.00% | -14.31% | -44.61% |
| Gross Margin | 0.00% | 82.07% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.71 | 1.14 | 1.27 | 0.52 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.71% | 23.85% | 66.63% | 2,083,137.68% |
| Free Cash Flow Growth | 17.25% | 11.31% | -30.59% | -21.65% |
| Safety | ||||
| Net Debt / EBITDA | 4.72 | 3.05 | 5.76 | 2.52 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -11.25 | -582.50 | 0.00 | 0.00 |